81 results about "Angiogenesis Effect" patented technology

Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a Dll4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and Dll4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.

The present invention provides a system for delivering a therapeutic agent into tissue in combination with an implant device (2). Preferably the therapeutic substance is contained within a pellet form (14) that is deliverable into the interior of the device (2) after it has been implanted. In a preferred embodiment the implant device (2) comprises a flexible coiled spring body, the coils (4) of which have the proper diameter and spacing to contain the pellet (14) within the interior of the device (2) to contact the therapeutic agent. In treatment of ischemic tissue such as that of the myocardium of the heart, the mechanical irritation of the tissue caused by the implanted device (2) can help to provide an angiogenic effect. Additionally, the cavity (18) provided by the interior of the device (2) permits blood to pool around the pellet (14) and mix with the therapeutic agent. Several delivery systems have provided for delivering the implant and pellet (14) sequentially or simultaneously.

Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.

DII4-binding molecules, preferably DII4-binding immunoglobulin single variable domains like VHHs and VHs, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with DII4-mediated effects on angiogenesis. Bispecific DII4-binding molecules that also bind to VEGF-A. Nucleic acids encoding DII4-binding molecules, host cells and methods for preparing same.

The invention discloses a scorpion venom extract extracted from East Asia scorpions. A preparation method for the scorpion venom extract comprises the following steps: scorpion venom freeze-dried powder is dissolved, centrifuged, filtered by use of 0.45 mu m and 0.22 mu m microporous membranes and freeze-dried; sephadex is added in; III-IV protein peaks of scorpion venom are collected; cation exchange chromatography is carried out; detection is carried out by use of an ultraviolet spectrophotometer; and the protein peaks are collected, so as to obtain the scorpion venom extract. Experiments prove that the scorpion venom extract has definite functions of inhibiting angiogenesis and hepatoma cell reincrease value. The invention successfully extracts effective components inhibiting angiogenesis and hepatoma cell reincrease value from the East Asia scorpions, which provides a foundation for further research and application in the future.

The invention relates to a method for quickly and quantitatively evaluating a blood vessel generation promotion function of chemical compounds on zebra fish. According to the method, transgenic zebra fish with blood vessels specially expressing green fluorescent protein are adopted, a to-be-detected medicine is directly added to water for culturing the zebra fish, the relative area of tail venous rete of the zebra fish is detected, and the method for quickly and quantitatively evaluating the blood vessel generation promotion function of the chemical compounds on the zebra fish is established and used for medicine screening. In the experiments of the zebra fish, the relative area of the tail venous rete is initially taken as a new evaluation index about the blood vessel generation function, whether the to-be-detected medicine has a blood vessel generation promotion function is analyzed more scientifically and more objectively, and the accuracy of results is improved.

Application of ginsenoside IH901 in preparing angiogenesis inhibitors relates to the application of the ginsenoside IH901 in the medicament field. The invention provides application of ginsenoside IH901 and a precursor thereof in preparing angiogenesis inhibitors. The ginsenoside IH901 is 20-O-beta-D-glucopyranoside-20(S)-protopanoxadiol which can be used for preparing the angiogenesis inhibitors, and the precursor of the ginsenoside IH901 can be used for preparing the angiogenesis inhibitors. The extracted ginsenoside IH901 and the precursor have inhibitory effect on infiltration metastasis and angiogenesis and are used for preparing medicaments for treating diseases related to tumor angiogenesis and other angiogenesis. The ginsenoside IH901 and precursor are prepared into anti-tumor drugs and other drugs for angiogenesis, thus providing a research base for pharmacodynamics and action mechanism and having values of developing the ginsenoside IH901 and the precursor into drugs for tumor chemotherapy and/or auxiliary chemotherapy.

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

The invention relates to a human Bcl-2 and human VEGF165 double-gene co-expression recombinant vector and a building method thereof, and is characterized in that IRES segment is utilized to connect an hBc1-2 gene and an hVEGF165 gene, and homologous recombination mechanisms in bacterium are utilized to recombine and build the human Bcl-2 and human VEGF165 double-gene co-expression recombinant vector according to an AdEasy system. The invention leads the Bcl-2 gene with anti-apoptosis capacity and the VEGF165 gene which currently promotes angiogenesis cytokine with strongest function to recombine on a same vector to be co-expressed, and solves the problem of low survival rate of transplanted cells under the condition of hypoxia and inflammation, simultaneously plays the function of promoting angiogenesis of VEGF165, plays an important part in the gene therapy of myocardial infarction and the cell transplantation research field, and has wide application prospect.

The present invention provides an in vitro method of assaying angiogenic effects, using the morphology of an in vitro model prepared by culturing endothelial cells in a three-dimensional collagen fiber gel as an index. The invention also provides a method for screening of prospective pro- and anti-angiogenic compounds.

The invention relates to application of carnosic acid in preparing a medicament for suppressing angiogenesis. The invention has the advantages that: the novel application of the carnosic acid discovers the effect of the carnosic acid in resisting angiogenesis for the first time, and the carnosic acid can effectively suppress proliferation, migration and canaliculization of vascular endothelial cells for the first time, which proves that the carnosic acid has the activity of resisting the angiogenesis, can be used as an angiogenesis suppressant, and can be applied to preparation of angiogenesis medicaments as the angiogenesis suppressant to treat neovascularization dependent and neovascularization related diseases, such as tumors, arthritis, psoriasis, ocular diseases, atherosclerosis, and the like.

The invention relates to a nerve repair drug-carrying system with bioelectrical stimulation and angiogenesis promoting effects and a preparation method thereof. Gelatin, chitosan, polylactic acid andother natural polymer components in the nerve repair drug-carrying system ensure good biocompatibility and no toxicity, polylactic acid can also meet the good mechanical property requirement of a catheter, catheter collapse in the nerve growth process is avoided, and excellent flexibility enables the nerve repair drug-carrying system not to hinder nerve regeneration. Due to the introduction of a conductive copolymer GO, the catheter has weak conductivity, meets the requirement of physiological current of a human body, and is beneficial to accelerating nerve repair; and by introducing a VEGF growth factor, an extracellular matrix microenvironment in a human body can be simulated to the maximum extent, nerve repair is promoted from the microvascular regeneration acceleration direction, and finally the nerve injury repair quality is improved.

The present invention provides a peptide or protein having a neovascularization action and containing a basic amino acid cluster region of β1,6-N-acetylglucosaminyltransferase, a neovascularization accelerator containing the above-mentioned peptide or protein, a method of screening an inhibition substance for the above-mentioned peptide or protein, and a neovascularization inhibitor containing this inhibition substance.

The invention relates to application of total triterpenes in preparing drugs inhibiting angiogenesis. The application has the advantages that novel application of the total triterpenes in extractive of Actinidia chinensis roots is provided. An experiment proves that the total triterpenes 1,2,3,4 have remarkable inhibiting effect on multiplication of human umbilical vein endothelial cells (HUVEC) and canaliculization of HUVEC, have anti-angiogenic activity, and can serve as angiogenesis inhibitors. By means of the application of the total triterpenes in preparing the drugs inhibiting the angiogenesis, the anti-angiogenesis effect of the total triterpenes in the extractive of Actinidia chinensis roots is firstly found out, and the total triterpenes can serve as the angiogenesis inhibitors to be applied to treat new blood vessel dependence and new vessel related diseases including tumors, arthritis, skin and eye diseases, atherosclerosis and the like.

The invention belongs to the technical field of biological materials and biological medicines, and discloses an oxidase-loaded microneedle for promoting wound healing of diabetics and a preparation method thereof.The preparation method comprises the steps that SilMA is dissolved in deionized water, and a photoinitiator HMPP is added under the dark condition to obtain a mixed solution A; adding PBZs and VEGF solution into the mixed solution A to obtain a mixed solution B; adding the mixed solution A into a polymyxin solution to obtain a mixed solution C; and respectively adding the mixed solution B and the mixed solution C into a microneedle mold, carrying out crosslinking under ultraviolet light, and separating the mold to obtain the composite microneedle. The PBZs and the VEGF are creatively loaded into the SilMA composite hydrogel microneedle to treat diabetic skin wounds, the oxidative stress level of diabetic skin wound tissues can be effectively relieved, a proper oxidation microenvironment is provided for the VEGF to play a role in promoting angiogenesis, and healing of the diabetic skin wounds can be better promoted.

There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.

The invention relates to application of dehydrocostuslactone to preparing a drug for inhibiting angiogenesis. The invention has the advantages of providing the novel application of the dehydrocostuslactone, finding the anti-angiogenesis of the dehydrocostuslactone for the first time, finding that the dehydrocostuslactone can effectively inhibit the multiplication, the migration and the canaliculization of vascular endothelial cells for the first time, showing that the dehydrocostuslactone has the activity of the anti-angiogenesis and can be used as an angiogenesis inhibitor as well as can be used as the angiogenesis inhibitor used for preparing the angiogenesis drug and treating vascularization dependent and vascularization relevant diseases of tumors, arthritis, parapsoriasis guttata, eye disorders, atherosclerosis and the like.

The invention discloses an improved endothelium growth factor polypeptide fragment of blood vessel and an application thereof. A polypeptide amino acid, the sequence of which is AHKRKRKKRHYK, compete with and antagonize the promotion effect of angiogenesis of VEGF by the distinguished combination with a VEGF acceptor and are used to prepare anti-tumor angiogenesis drugs; moreover, radionuclide marks used to prepare tumor nuclide developing drugs and internal irradiation of radioactive nuclide drugs can be further made; the appetency between the polypeptide of the invention and the VEGF acceptor is obviously higher than VEGF125-136; S-acetyl-MAG3 is used as a double function chelating agent to make the radionuclide marks for the polypeptide, and the mark rate is more than 95 percent, moreover, the marks are good in stability, do not need to be purified and can be directly used.

The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

An angiogenesis promoter containing a compound of the following formula (I) <CHEM> wherein R<1> is acyl, R<2> is alkyl, R<3> and R<4> are the same or different and each is hydrogen atom or hydroxy protecting group and R<5> is alkyl, as an active ingredient. This compound itself not only has an angiogenesis promoting effect but also potentiates the angiogenic effect by a drug (e.g., b-FGF) having such effect. Therefore, it can express the angiogenesis promoting effect more effectively in the ischemic tissues and the site under different disease state, where b-FGF has locally increased.

The invention relates to a method for evaluating the effect of a compound on angiogenesis in a pathological state. According to the invention, a vascular endothelial growth factor (VEGF) is used for treating young zebra fish in a specific period to simulate a pathological state, then complete subintestinal peripheral vein length is used as an evaluation index, so the evaluation method for the effect of a drug on angiogenesis in the pathological state is successively established. The method has the advantages of simple operation, rapidness, stability, reliability and good repeatability, is more scientific and objective, presents the generation condition of spinous process and improves accuracy of results.

The present patent application relates to the use of triazine derivatives as cicatrising or angiogenic agents, wherein the triazine is a molecule of formula (I).